Old Articles: <Older 8081-8090 Newer> |
|
The Motley Fool November 25, 2011 Brian Orelli |
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. |
The Motley Fool November 25, 2011 |
A Brief History of Eli Lilly's Returns The good news is that, with shares now trading at around 10 times earnings, Eli Lilly looks reasonably valued, if not cheap. |
The Motley Fool November 25, 2011 Dan Caplinger |
Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs. |
The Motley Fool November 23, 2011 Brian Orelli |
I Was Wrong About Dendreon But maybe not in the long term. |
The Motley Fool November 22, 2011 Brian Orelli |
This Spec Pharma Hopes Convenience Trumps All Spectrum Pharmaceuticals' Zevalin no longer requires a bioscan. |
The Motley Fool November 22, 2011 Brian Orelli |
A Little Diversity Goes a Long Way Especially in this economy. |
The Motley Fool November 22, 2011 Luke Timmerman |
Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring Pfizer is making a new bet on a new drug to fight excessive scarring. |
The Motley Fool November 22, 2011 Selena Maranjian |
Make Money in Global Health-Care Stocks the Easy Way If you expect the global health-care industry to thrive as our planet's population grows and ages, the iShares S&P Global Health Care ETF could save you a lot of trouble. |
The Motley Fool November 21, 2011 David Williamson |
Market Volatility = Biotech Opportunity Gilead buys Pharmasset, Spectrum gets a break, and Eylea's approved. |
Fast Company November 19, 2011 Tristram Korten |
Cracking Down On $70 Billion Worth Of Medicare Fraud A pharmacy run out of this storefront near Miami billed a federal agency for $776,298 - in just nine days. There were no real employees. There were no real patients. There were no real prescriptions. How medical fraud has become an untreated epidemic. |
<Older 8081-8090 Newer> Return to current articles. |